Innovation in Women and Infant Healthcare

There is a tremendous need for progress in healthcare solutions devoted to women and babies, but ironically, this field has historically been underdeveloped and underfunded in terms of medical innovation. Every year, globally, more than three million babies die on the day they draw their first breaths, and 300,000 women perish in the process of delivery. We are working to drastically lower these numbers. We identified entrepreneurs who had the best new ideas, and brought them to the Institute to allow them to benefit from our resources to bring their products to market faster. Our in-residence companies are creating technology to treat some of the most common, and deadly, health problems:


Company Technology Patient Benefit
InPress Technologies.

New Press Release

Developed a simple device that is intended to quickly and effectively stop postpartum hemorrhage (PPH), the leading cause of maternal death globally, which takes the life of one woman every four minutes.

View company flyer
By avoiding the use of pharmaceuticals, hysterectomy, or other invasive surgical procedures, InPress can dramatically reduce the cost of healthcare during childbirth and save women's lives.
Madorra Madorra is developing the first, non-hormonal, medical device treatment for vaginal dryness and atrophy, which will improve the quality of life for breast cancer survivors and post-menopausal women. Renewing vaginal tissue and eliminating vaginal dryness could have a profound impact on women, particularly cancer survivors and post-menopausal women. There are 1.4 million breast cancer survivors in the United States who suffer from vaginal atrophy.
Materna Medical Working to reduce the incidence of childbirth-related injuries, and the lifelong consequences most women experience as result of vaginal delivery.

View company flyer
Our device is designed to prevent vaginal tearing and pelvic floor damage that commonly occurs during childbirth.

Marz Medical

Marz Medical is developing a technology aimed at reducing pain and recovery time for patients undergoing breast or burn reconstruction surgery. The technology will help mastectomy patients, and also individuals who suffered from burns anywhere on their body. Significantly, the technology has already received FDA approval to assist with tissue expansion needed during reconstructive surgery. One in eight women are diagnosed with cancer each year and about 100,000 women undergo mastectomy in the U.S.
Medical Cue Solving a major need in newborn monitoring and resuscitation by automatically sensing key physiologic data and making this information easily available to assist caregivers. More than one million babies die annually from birth asphyxia.

View company flyer
Improving newborn care in the labor and delivery and in the NICU. MedicalCue is committed to improving outcomes for newborns.
nVision Developing two devices – the first will significantly advance the diagnosis of the leading cause of female infertility, fallopian tube blockage. The second device will allow gynecologists to collect cells from the fallopian tube to further explore a patient's symptoms, including early detection of ovarian cancer, which is perhaps the biggest unmet need in all of women's health.

The first is a device which will significantly advance the diagnosis of the leading cause of female infertility, fallopian tube blockage. The second device will allow gynecologists to collect cells from the fallopian tube to further explore a patient's symptoms.
Ann Fyfe

"We offer entrepreneurs everything they need to take an idea from initiation to application. It's an incredibly exciting environment."

– Ann Fyfe, President/CEO, FII